IPCA Laboratories Limited has informed the Exchange about Transcript of Conference Call held on 30th May, 2025
IPCALAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ipca Labs reported strong FY25 results with consolidated EBITDA margins improving to 18.94% (from 16.72%), beating the earlier 18% guidance. Standalone FY25 EBITDA margin rose 337 bps to 22.66%, and Q4 margin jumped to 21.19% from 18.5%. Domestic business grew ~12% for the full year, with metro market share improving 9 bps to 2.07%. Unichem (acquired subsidiary) revenue grew 13% to INR2,011 cr with EBITDA margin expanding sharply from 4.87% to 12.55%. For FY26, management guided 8-10% revenue growth and EBITDA margin improvement to ~20% on a consolidated basis. Capex of ~INR1,000 cr is planned across FY25-FY26 covering a Pithampur biosimilar facility, Dewas formulation plant, Nagpur API facility, and a North Carolina injectable unit. The US business, though small at ~INR25 cr, is targeted to scale to INR300-400 cr in 3-4 years with 6-7 ANDA filings planned this year.
Positive for shareholders: management beat prior margin guidance and is guiding further expansion to 20% in FY26, with Unichem synergies expected to add upside in the next 2-3 years. The US pipeline, capacity expansion, and improving metro share are key growth levers, though heavy capex (~INR1,000 cr over two years) and South Africa/CIS softness are watch points.